-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AXA Pharma today announced a global clinical research partnership with Mercado, a company based in Kenneworth Merck, New Jersey, USAThe two sides will conduct clinical studies on the combination of APG-115, the original MDM2-p53 inhibitor, and Mercado's PD-1 monoanti-KEYTRUDA®
(Pabolizhu monosar) to evaluate the clinical effects of the combination drug in patients with advanced solid tumorsbased on the terms of cooperation, AXA Pharma will support this multi-center, open Ib/II clinical study aimed at evaluating the safety and effectiveness of APG-115 joint KEYTRUDA®
treatment of a wide range of solid tumors, including non-small cell lung cancer, melanoma, and urethra Patients with attM mutations/p53 wild tumors treated with PD-1/PD-L1, etc., such as cancer, lipoma, malignant peripheral neuroblastoma, and treatment with PD-1/PD-L1The study is now in Phase II clinical trials and plans to recruit a total of 80 patients in multiple u.ScountriesAsain Pharma and Mercado will share relevant research information through the Joint Development Committeepreclinical studies show that APG-115 can promote the production of T-cell prosteritiscyte cytokines, enhance the activation of CD4-T cells, and improve the expression of PD-L1 in a variety of tumor cellsAntitumor activity after use of APG-115 combined PD-1 inhibitors was significantly enhanced in several tumor modelsThe results of the ib clinical trial in this study, presented at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO), showed that the combination of APG-115 and Paboli zuma saita had good resistance and significant antitumor activity in a variety of tumor typesKEYTRUDA®
is a registered trademark and the trademark is owned by Merck Sharp and Dohme Corp., a subsidiary of Mercerton, Kenneworth, New Jersey, USA